NCT02914626.

Trial name or title	Intravitreal ranibizumab (Lucentis®) for neovascular glaucoma – a randomised controlled study
Methods	Randomised controlled trial Number to be randomised: 28 (one study eye per participant) Follow‐up: 6 months
Participants	Country: Brazil People with neovascular glaucoma, older than 18 years of age Inclusion criteria: IOP greater than 24 millimeter of mercury Iris or anterior chamber neovascularization At least 120° of opened anterior chamber Exclusion criteria: Visual acuity worse than counting fingers in the fellow eye No light perception in the treated eye Any ocular infectious disease Use of systemic steroids Lack of media transparency precluding laser photocoagulation Thromboembolic disease Known hypersensitivity to ranibizumab Female participants at childbearing age not using oral contraceptives Use of intravitreal anti‐vascular endothelial growth factor over the last 30 days.
Interventions	Experimental group: standard of care therapy (retinal laser photocoagulation) plus two intravitreal ranibizumab injections 30 days apart Control group: standard of care therapy (retinal laser photocoagulation) plus sham injections
Outcomes	Primary outcome: IOP at 6 months Secondary outcomes: Anterior segment neovascularization at 6 months Best corrected visual acuity at 6 months Number of drugs needed for IOP control at 6 months Need for IOP control surgery at 6 months
Starting date	Study start date: October 2016
Contact information	Leandro Cabral Zacharias University of Sao Paulo General Hospital
Notes	Funded by Novartis Estimated Primary completion date: October 2017 Estimated study completion date: Ocober 2018 (Last update posted: September 27, 2016)

IOP: intraocular pressure